ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Decrease in Short Interest

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 129,600 shares, a decrease of 53.2% from the January 15th total of 276,800 shares. Currently, 5.5% of the company’s stock are sold short. Based on an average daily trading volume, of 836,000 shares, the short-interest ratio is presently 0.2 days.

ZyVersa Therapeutics Trading Up 4.0 %

ZyVersa Therapeutics stock opened at $1.31 on Thursday. The stock has a 50-day moving average of $1.24 and a two-hundred day moving average of $1.91. ZyVersa Therapeutics has a one year low of $0.98 and a one year high of $25.00.

Hedge Funds Weigh In On ZyVersa Therapeutics

An institutional investor recently bought a new position in ZyVersa Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned approximately 1.08% of ZyVersa Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 3.91% of the company’s stock.

ZyVersa Therapeutics Company Profile

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.